Amendments to the Claims

1. (currently amended) A compound of Formula I:



Formula I

wherein

X represents S;

R^1 represents hydrogen, F, Cl, Br, I, CHO, -CN, -S(phenyl), CF_3, -(1-4C)alkyl, -(1-4C)alkoxy, –S(1-4C)alkyl, –SO(1-4C)alkyl, $–SO_2$(1-4C)alkyl, -C(=O)(1-3C)alkyl, NH_2, -NH(1-4C)alkyl, -N[(1-4C)alkyl]$_2$, -NH(4-7C)cycloalkyl, or -N[(1-4C)alkyl]$(CH_2)_r$N[(1-4C)alkyl]$_2$;

R^2 represents–CO_2H;

R^4 represents hydrogen, OH, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2O$(1-4C)alkyl, F, Cl, CF_3, OCF_3, -CN, NO_2, NH_2, $-CH_2NH_2$, -(1-4C)alkyl, -(1-4C)alkoxy, -C(=O)NH(1-4C)alkyl, $-C(=O)NH_2$, $-CH_2C(=O)NH_2$, -NHC(=O)(1-4C)alkyl, $-(CH_2)_mNHSO_2R^{10}$, $-(CH_2)_nCN$, $-(CH_2)_mCO_2H$, $-C(=NOH)CH_3$, $-(CH_2)_mCO_2$(1-6C)alkyl, -C(=O)H, -C(=O)(1-4C)alkyl, -NH(1-4C)alkyl, -N[(1-4C)alkyl]$_2$, $-SR^{10}$, $-SOR^{10}$, $-SO_2R^{10}$, SH, $-CH_2SO_2NH_2$, $-CH_2NHC(=O)CH_3$,



;

R^5 represents hydrogen, F, Cl, -CN, NO_2, NH_2, $-(CH_2)_mNHSO_2R^{10}$, -(1-4C)alkyl, or -(1-4C)alkoxy;

R^6 represents hydrogen, -(1-4C)alkyl, $-SO_2R^{11}$, or -C(=O)(1-4C)alkyl;

R^7 represents hydrogen or -(1-4C)alkyl;

R^8 represents hydrogen, F, Cl, Br, -(1-4C)alkyl, -(1-4C)alkoxy, NO_2, NH_2, -CN, $-NHSO_2R^{11}$, or -C(=O)(1-4C)alkyl;

R^{8a} represents hydrogen, F, Cl, Br, -(1-4C)alkyl, NO_2, NH_2, NH(1-6C)alkyl, N[(1-6C)alkyl]$_2$, $-C(=O)NH_2$, -CN, $-CO_2H$, -S(1-4C)alkyl, $-NHCO_2$(1-4C)alkyl,

-C(=O)NHCH$_2$CH$_2$CN, or -C(=O)(1-4C)alkyl;

R^{10}, R^{11}, and R^{12} each independently represent –(1-4C)alkyl, -(CH$_2$)$_3$Cl, CF$_3$, NH$_2$, NH(1-4C)alkyl, N[(1-4C)alkyl)]$_2$, thienyl, phenyl, -CH$_2$phenyl, or –(CH$_2$)$_2$phenyl, wherein phenyl, as used in substituent R^{10}, R^{11} or R^{12}, is unsubstituted or substituted with F, Cl, Br, CF$_3$, –(1-4C)alkyl, -(1-4)alkoxy, or acetyl;

R^{13} represents hydrogen, -(1-4C)alkyl, -CH$_2$CF$_3$, triazole, or tetrazole;

R^{14} represents -(1-4C)alkyl;

R^{15} represents hydrogen or -(1-4C)alkyl;

R^{19} represents (1-4C)alkyl or CF$_3$;

m represents 0, 1, 2, or 3;

n represents 1, 2, 3, or 4;

p represents 1 or 2;

r represents 1 or 2; and

A is selected from the group consisting of -(CH$_2$)$_2$NHSO$_2$R^{12}, -CH(CH$_3$)(CH$_2$)NHSO$_2$R^{12}, -(CH$_2$)CH(CH$_3$)NHSO$_2$R^{12},



~~-OH, Br, I, CF$_3$, -(CH$_2$)$_m$CN, -C(CH$_3$)$_2$CN, NO$_2$, NH$_2$, -O(CH$_2$)$_n$NH$_2$, -O(CH$_2$)$_n$NHSO$_2$(1-4C)alkyl, -O(CH$_2$)$_n$SO$_2$(1-4C)alkyl, -C(=O)NH(CH$_2$)$_r$NHSO$_2$(1-4C)alkyl, -S(1-4C)alkyl, -(1-6C)alkyl, -(1-4C)alkoxy, -(2-4C)alkenyl, -(2-4C)alkenyloxy, -CO$_2$H, -CO$_2$(1-4C)alkyl, -CHO, -C(=O)(1-4C)alkyl, -C(=O)NH$_2$, -C(=O)NH(1-6C)alkyl, -C(=O)NR^{15}(CH$_2$)$_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO$_2$, NH$_2$, -NHSO$_2$(1-4C)alkyl, -CN, -(1-4C)alkyl, and -(1-4C)alkoxy; -OSO$_2$CF$_3$,~~

~~-O(CH$_2$)$_n$CN, -NHC(=O)(1-4C)alkyl, -NHC(=O)(CH$_2$)$_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO$_2$, NH$_2$, CN, (1-4C)alkyl and (1-4C)alkoxy; -(CH$_2$)$_m$NHSO$_2$R^{12}, -CH(CH$_3$)(CH$_2$)$_p$NHSO$_2$R^{12}, -(CH$_2$)$_p$CH(CH$_3$)NHSO$_2$R^{12}, -NH(CH$_2$)$_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO$_2$, NH$_2$, CN, -(1-4C)alkyl, and -(1-4C)alkoxy; -NH(1-4C)alkyl, -N[(1-4C)alkyl]$_2$, -C(=O)NH(3-6C)cycloalkyl, -C(=O)NH(CH$_2$)$_n$N[(1-4C)alkyl]$_2$, -C(=O)NH(CH$_2$)$_n$NH(1-4C)alkyl, -(CH$_2$)$_n$NH$_2$, -O(CH$_2$)$_n$SR^{14}, -O(CH$_2$)$_n$OR^{14}, -(CH$_2$)$_n$NHR^{12}, -(CH$_2$)$_n$NH(3-6C)cycloalkyl, -(CH$_2$)$_n$N[(1-4C)alkyl]$_2$, -CH$_2$NHC(=O)CH$_3$, -NHC(=O)NHR^{12}, -NHC(=O)N[(1-4C)alkyl]$_2$,~~



and the pharmaceutically acceptable salts thereof, provided that when R^1 is S(1-4C)alkyl, A is not CF_3, -(1-6C)alkyl, or -(1-4C)alkoxy.

2. (Canceled).

3. (Canceled).

4. (Canceled).

5. (Canceled).

6. (Canceled).

7. (currently amended) A compound according to claim ~~2~~ [1] wherein A is



.

8. (Canceled).

9. (Original). A compound according to claim 1 wherein R^1 represents hydrogen, $-SCH_3$, CF_3, methyl, or ethyl.

10. (Canceled).

11. (previously presented) A compound according to claim 7 wherein R^5 represents hydrogen, F, Cl, or –(1-4C)alkyl.

12. - 14. (Canceled).

15. (previously presented) A compound according to claim 11 wherein R^4 represents hydrogen, -CN, ethoxy, or $–SCH_3$.

16. – 41. (Canceled).

42. (currently amended) A pharmaceutical composition comprising, a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient:



Formula I

wherein

X represents S;

R^1 represents hydrogen, F, Cl, Br, I, CHO, -CN, -S(phenyl), CF_3, -(1-4C)alkyl, -(1-4C)alkoxy, –S(1-4C)alkyl, –SO(1-4C)alkyl, $–SO_2$(1-4C)alkyl, -C(=O)(1-3C)alkyl, NH_2, -NH(1-4C)alkyl, -N[(1-4C)alkyl]$_2$, -NH(4-7C)cycloalkyl, or -N[(1-4C)alkyl]$(CH_2)_r$N[(1-4C)alkyl]$_2$;

R^2 represents—CO_2H;

R^4 represents hydrogen, OH, $-CH_2OH$, $-CH_2CH_2OH$, $-CH_2O$(1-4C)alkyl, F, Cl, CF_3, OCF_3, -CN, NO_2, NH_2, $-CH_2NH_2$, -(1-4C)alkyl, -(1-4C)alkoxy, -C(=O)NH(1-4C)alkyl, $-C(=O)NH_2$, $-CH_2C(=O)NH_2$, -NHC(=O)(1-4C)alkyl, $-(CH_2)_mNHSO_2R^{10}$, $-(CH_2)_nCN$, $-(CH_2)_mCO_2H$, $-C(=NOH)CH_3$, $-(CH_2)_mCO_2$(1-6C)alkyl, -C(=O)H, -C(=O)(1-4C)alkyl, -NH(1-4C)alkyl, -N[(1-4C)alkyl]$_2$, $-SR^{10}$, $-SOR^{10}$, $-SO_2R^{10}$, SH, $-CH_2SO_2NH_2$, $-CH_2NHC(=O)CH_3$,



;

R^5 represents hydrogen, F, Cl, -CN, NO_2, NH_2, $-(CH_2)_mNHSO_2R^{10}$, -(1-4C)alkyl, or -(1-4C)alkoxy;

R^6 represents hydrogen, -(1-4C)alkyl, $-SO_2R^{11}$, or -C(=O)(1-4C)alkyl;

R^7 represents hydrogen or -(1-4C)alkyl;

R^8 represents hydrogen, F, Cl, Br, -(1-4C)alkyl, -(1-4C)alkoxy, NO_2, NH_2, -CN, $-NHSO_2R^{11}$, or -C(=O)(1-4C)alkyl;

R^{8a} represents hydrogen, F, Cl, Br, -(1-4C)alkyl, NO_2, NH_2, NH(1-6C)alkyl, N[(1-6C)alkyl]$_2$, $-C(=O)NH_2$, -CN, $-CO_2H$, -S(1-4C)alkyl, $-NHCO_2$(1-4C)alkyl, $-C(=O)NHCH_2CH_2CN$, or -C(=O)(1-4C)alkyl;

R^{10}, R^{11}, and R^{12} each independently represent –(1-4C)alkyl, $-(CH_2)_3Cl$, CF_3, NH_2, NH(1-4C)alkyl, N[(1-4C)alkyl)]$_2$, thienyl, phenyl, $-CH_2$phenyl, or $–(CH_2)_2$phenyl, wherein phenyl, as used in substituent R^{10}, R^{11} or R^{12}, is unsubstituted or substituted with F, Cl, Br, CF_3, –(1-4C)alkyl, -(1-4)alkoxy, or acetyl;

R^{13} represents hydrogen, -(1-4C)alkyl, $-CH_2CF_3$, triazole, or tetrazole;

R^{14} represents -(1-4C)alkyl;

R^{15} represents hydrogen or -(1-4C)alkyl;

R^{19} represents (1-4C)alkyl or CF_3;

m represents 0, 1, 2, or 3;

n represents 1, 2, 3, or 4;

p represents 1 or 2;

r represents 1 or 2; and

A is selected from the group consisting of –OH, CF_3, -$(CH_2)_m$CN, -$C(CH_3)_2$CN, NO_2, NH_2, -$O(CH_2)_nNH_2$, -$O(CH_2)_nNHSO_2$(1-4C)alkyl, -$O(CH_2)_nSO_2$(1-4C)alkyl, -$C(=O)NH(CH_2)_rNHSO_2$(1-4C)alkyl, -S(1-4C)alkyl, -(1-6C)alkyl, -(1-4C)alkoxy, -(2-4C)alkenyl, -(2-4C)alkenyloxy, -CO_2H, -CO_2(1-4C)alkyl, -CHO, -C(=O)(1-4C)alkyl, -$C(=O)NH_2$, -C(=O)NH(1-6C)alkyl, -$C(=O)NR^{15}(CH_2)_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO_2, NH_2, -$NHSO_2$(1-4C)alkyl, -CN, -(1-4C)alkyl, and –(1-4C)alkoxy; -OSO_2CF_3, -$O(CH_2)_n$CN, -NHC(=O)(1-4C)alkyl, -$NHC(=O)(CH_2)_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO_2, NH_2, CN, -(1-4C)alkyl and –(1-4C)alkoxy; -$(CH_2)_mNHSO_2R^{12}$, -$CH(CH_3)(CH_2)_pNHSO_2R^{12}$, -$(CH_2)_pCH(CH_3)NHSO_2R^{12}$, -$NH(CH_2)_m$phenyl wherein phenyl is unsubstituted or substituted with one or two substituents independently selected from the group consisting of OH, F, Cl, Br, I, NO_2, NH_2, CN, -(1-4C)alkyl, and –(1-4C)alkoxy; -NH(1-4C)alkyl, -$N[(1\text{-}4C)alkyl]_2$, -C(=O)NH(3-6C)cycloalkyl, -$C(=O)NH(CH_2)_nN[(1\text{-}4C)alkyl]_2$, -$C(=O)NH(CH_2)_n$NH(1-4C)alkyl, -$(CH_2)_nNH_2$, -$O(CH_2)_nSR^{14}$, -$O(CH_2)_nOR^{14}$,-$(CH_2)_nNHR^{12}$, -$(CH_2)_n$NH(3-6C)cycloalkyl, -$(CH_2)_nN[(1\text{-}4C)alkyl]_2$, -$CH_2NHC(=O)CH_3$, -$NHC(=O)NHR^{12}$, -$NHC(=O)N[(1\text{-}4C)alkyl]_2$,



and the pharmaceutically acceptable salts thereof, provided that when R^1 is S(1-4C)alkyl, A is not CF_3, -(1-6C)alkyl, or -(1-4C)alkoxy.